NASDAQ:TBPH

Theravance Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy TBPH

*Your capital is at risk

$15.92

+0.340 (+2.18%)

At Close: Jun 03, 2026

Theravance Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -73.79. In total, the insiders bought 724.98K and sold 848.32K TBPH shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-73.79
● Buy	724.98K shares
● Sell	848.32K shares
38% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Apr 01, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -73.79. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	O'connor Donal Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Mitchell Dean J Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Mitchell Dean J Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Gray Susannah Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Gray Susannah Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Grant Jeremy T Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Grant Jeremy T Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Broshy Eran Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Broshy Eran Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Smaldone Alsup Laurie Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Smaldone Alsup Laurie Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Smaldone Alsup Laurie Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Smaldone Alsup Laurie Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Broshy Eran Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Broshy Eran Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Grant Jeremy T Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Grant Jeremy T Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Gray Susannah Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Gray Susannah Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Mitchell Dean J Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Mitchell Dean J Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	O'connor Donal Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	O'connor Donal Director	Director	10 649 Value: $100.0K
May 19, 2025 Buy	Share Option (Right to Buy) A-Award	Pakianathan Deepika Director	Director	24 258 Value: $227.8K
May 19, 2025 Buy	Ordinary Shares A-Award	Pakianathan Deepika Director	Director	10 649 Value: $100.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT THERAVANCE BIOPHARMA

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical tr...

Read Full Profile Here